
    
      The purpose of this study is to evaluate the combination of panitumumab and TAS-102 in
      patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard
      chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan and angiogenesis inhibitors).

      Patients who are judged eligible for the study based on the inclusion and exclusion criteria
      will be received panitumumab (6 mg/kg) every 2 weeks and TAS-102 (35 mg/mÂ² given orally twice
      a day in a 28-day) in 2-week cycle of 5 days of treatment followed by a 2-day rest period,
      and then a 14-day rest period.

      A maximum of 58 participants will be enrolled.
    
  